JHVEPhoto
- Inspire Medical Systems (NYSE:INSP) and ResMed (NYSE:RMD) are both down significantly in Monday trading, apparent casualties of positive data released after the closing bell on June 21 of Eli Lilly’s (LLY) diabetes and weight loss drug tirzepatide as a sleep apnea treatment.
- Inspire manufactures an implantable neurostimulation device for obstructive sleep apnea (OSA), while ResMed is a top maker of CPAP (continuous positive airway pressure) machines, considered the gold standard for treatment of OSA.
- Inspire is off ~18%, while ResMed is down ~12%.
- AdaptHealth (AHCO), which sells home medical equipment including CPAP machines, is down ~7%.